Catalyst
Slingshot members are tracking this event:
BioMarin (BMRN) C1-INH treatment of hereditary angioedema granted FDA orphan designation
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMRN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 20, 2021
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Hereditary Angioedema
